Program supports the Medidata Patient, Data, and Study Experiences, boosting site engagement, eliminating clinical trial inefficiencies, and increasing tech compliance
NEW YORK, March 27, 2025--(BUSINESS WIRE)--Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced that it has introduced its Medidata Site Insights Program, a collection of initiatives to accelerate the delivery of life-changing therapies to patients. The new framework will help promote a more open dialogue with sites, transforming the clinical trial ecosystem, spearheading innovation, and reducing technological burden.
"At the heart of Medidata is the steadfast vision to fundamentally transform the clinical trial ecosystem. Dedicated to eliminating inefficiencies that delay progress, our mission is to cultivate a world-class site experience through direct and open collaboration with these critical stakeholders," said Robin Douglas, vice president, research site engagement, Medidata. "By including the site voice in our ongoing discussions, we're not just streamlining clinical trial processes and enhancing technology but helping our clients to deliver effective treatments to patients sooner."
According to WCG's 2023 Clinical Research Site Challenges Report, 47% of sites find it difficult to adopt new technologies and systems. Medidata’s transformative program seeks to address this issue through both existing and new initiatives:
To learn more about the Site Insights Program, visit here.
About Medidata
Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 35,000 trials and 11 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across approximately 2,300 customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata.
About Dassault Systèmes
Dassault Systèmes is a catalyst for human progress. Since 1981, the company has pioneered virtual worlds to improve real life for consumers, patients and citizens. With Dassault Systèmes’ 3DEXPERIENCE platform, 370,000 customers of all sizes, in all industries, can collaborate, imagine and create sustainable innovations that drive meaningful impact. For more information, visit: www.3ds.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250327471618/en/
Contacts
Medidata PR
Medidata.PR@3ds.com
Analyst Relations
medidata.AR@3ds.com
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.